MovDisordV3, PubMed, Curation, bibRecord, 002F00

Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.

Identifieur interne : 002F00 ( PubMed/Curation ); précédent : 002E99; suivant : 002F01

Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.

Auteurs : Inger Marie Skogseid [Norvège] ; Jo R Islien ; Bj Rgulf Claussen ; Emilia Kerty

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.

RBID : pubmed:16114026

English descriptors

KwdEn :
- Adult, Aged, Anti-Dyskinesia Agents (therapeutic use), Botulinum Toxins (therapeutic use), Chi-Square Distribution, Demography, Employment, Female, Humans, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Time Factors, Torticollis (drug therapy), Torticollis (psychology).
MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug therapy : Torticollis.
- psychology : Torticollis.
- Adult, Aged, Chi-Square Distribution, Demography, Employment, Female, Humans, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Time Factors.

Abstract

We examined the impact of cervical dystonia (CD) and long-term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long-term treatment were obtained from 62 CD patients aged 31-66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5-10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long-term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated.

DOI: 10.1002/mds.20670
PubMed: 16114026

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F00

Links to Exploration step

pubmed:16114026

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.</title>
<author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo, Norway. i.m.skogseid@klinmed.uio.no</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name>
</author>
<author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name>
</author>
<author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="doi">10.1002/mds.20670</idno>
<idno type="RBID">pubmed:16114026</idno>
<idno type="pmid">16114026</idno>
<idno type="wicri:Area/PubMed/Corpus">002F00</idno>
<idno type="wicri:Area/PubMed/Curation">002F00</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.</title>
<author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo, Norway. i.m.skogseid@klinmed.uio.no</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name>
</author>
<author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name>
</author>
<author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Chi-Square Distribution</term>
<term>Demography</term>
<term>Employment</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
<term>Time Factors</term>
<term>Torticollis (drug therapy)</term>
<term>Torticollis (psychology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Chi-Square Distribution</term>
<term>Demography</term>
<term>Employment</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We examined the impact of cervical dystonia (CD) and long-term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long-term treatment were obtained from 62 CD patients aged 31-66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5-10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long-term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16114026</PMID>
<DateCreated><Year>2005</Year>
<Month>11</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>2006</Year>
<Month>03</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>20</Volume>
<Issue>12</Issue>
<PubDate><Year>2005</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.</ArticleTitle>
<Pagination><MedlinePgn>1604-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We examined the impact of cervical dystonia (CD) and long-term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long-term treatment were obtained from 62 CD patients aged 31-66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5-10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long-term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skogseid</LastName>
<ForeName>Inger Marie</ForeName>
<Initials>IM</Initials>
<AffiliationInfo><Affiliation>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo, Norway. i.m.skogseid@klinmed.uio.no</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Røislien</LastName>
<ForeName>Jo</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Claussen</LastName>
<ForeName>Bjørgulf</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kerty</LastName>
<ForeName>Emilia</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018726">Anti-Dyskinesia Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018726">Anti-Dyskinesia Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001905">Botulinum Toxins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016009">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003710">Demography</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D004651">Employment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D014103">Torticollis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>8</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>3</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>8</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20670</ArticleId>
<ArticleId IdType="pubmed">16114026</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F00 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002F00 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:16114026
   |texte=   Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:16114026" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.

Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki